Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Overview

This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.

Full Title of Study: “A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: September 1, 2024

Detailed Description

As there is a strong association between PSC and IBD, it is reasonable to hypothesize that a therapy of proven benefit for UC may prove to also be effective for PSC. Unfortunately, several therapies which are indicated for the treatment of UC have not been effective in PSC including anti-TNF therapies and other anti-inflammatory medications. Sulfasalazine and mesalamine, medications commonly used for the treatment of UC, may be exceptions to this trend. While this therapy has never been formally tested in PSC, some retrospective reports suggest a possible benefit. Our current understanding of the mechanism of action of these medications suggests there is reasonable to believe they may also be effective in PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.

Interventions

  • Drug: Sulfasalazine
    • Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
  • Drug: Placebo
    • Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.

Arms, Groups and Cohorts

  • Active Comparator: Active Drug (Sulfasalazine)
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Reduction in Mean Alkaline Phosphatase (ALP)
    • Time Frame: Baseline through the end of the Study at Week 22
    • Proportion of patients with reduction of mean ALP < 1.5 x ULN at end of treatment
  • Normalization of ALP below the upper limit of normal
    • Time Frame: Baseline through the end of the Study at Week 22
    • Assessment in number of patients whose ALP normalizes

Secondary Measures

  • Overall changes in ALP levels
    • Time Frame: Baseline through the end of the Study at Week 22
    • Proportion of patients with ALP > or < 1.5 x ULN at end of treatment
  • Changes in blood tests
    • Time Frame: Baseline through the end of the Study at Week 22
    • Change in mean Liver Function Tests (e.g. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), total bilirubin) and C-reactive Protein
  • Adverse Events
    • Time Frame: Baseline through the end of the Study at Week 22
    • Unexpected and Serious Adverse Events will be examined
  • Changes in Mayo PSC risk score
    • Time Frame: Baseline through the end of the Study at Week 22
    • Number of patients with changes in Mayo PSC risk score
  • Changes in Modified Fatigue Scale (MFS)
    • Time Frame: Baseline through the end of the Study at Week 22
    • Number of patients with changes in MFS score
  • Changes in pruritus visual analog scale (VAS)
    • Time Frame: Baseline through the end of the Study at Week 22
    • Number of patients with changes in VAS score

Participating in This Clinical Trial

Inclusion Criteria

1. Age 15-80 2. A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC. 3. ALP > 1.67 times the upper limit of normal (ULN) at screening 4. Inflammatory bowel disease 5. Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months prior to screening or have been discontinued > 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 50% of all enrolled patients). We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled. Exclusion Criteria:

1. Anticipated need for liver transplant within one year as determined by Mayo PSC risk score treatment 2. Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy. 3. Evidence of advanced liver disease including MELD score > 10, bilirubin > 3.0, platelet count < 100,000; or INR > 1.4 4. Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis 5. Secondary causes of sclerosing cholangitis 6. Known intolerance to sulfasalazine (including but not limited to allergy to sulfa or mesalamine) or folic acid 7. History of cholangiocarcinoma or colon cancer within 5 years 8. History of colectomy with > 1/3 bowel resected 9. Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer. 10. Active illicit drug or alcohol abuse 11. Current or past use of sulfasalazine within 6 months of enrollment. 12. Need for chronic use of antibiotics 13. Evidence of bacterial cholangitis within 6 months of enrollment 14. In patients with Ulcerative Colitis, simple clinical colitis activity index of > 4 or, if Crohn's disease, a Harvey-Bradshaw index of > 5 15. Chronic kidney injury (eGFR < 59) 16. Pregnancy or lactation

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Brigham and Women’s Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Joshua Korzenik, Director, Crohn’s and Colitis Center – Brigham and Women’s Hospital
  • Overall Official(s)
    • Joshua R Korzenik, MD, Principal Investigator, Brigham and Women’s Hospital
  • Overall Contact(s)
    • Charu Madhwani Jain, MD, MPH, 617-732-9119, cmjain@bwh.harvard.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.